HPLC for Pharmaceutical Scientists
This price is valid for United States. Change location to view local pricing and availability.
Other Available Formats: Hardcover
PART I HPLC THEORY AND PRACTICE.
1 Introduction (Yuri Kazakevich and Rosario LoBrutto).
1.1 Chromatography in the Pharmaceutical World.
1.2 Chromatographic Process.
1.4 History of Discovery and Early Development (1903-1933).
1.5 General Separation Process.
1.6 Types of HPLC.
1.7 HPLC Descriptors (Vr, k, N, etc.).
2 HPLC Theory (Yuri Kazakevich).
2.2 Basic Chromatographic Descriptors.
2.5 HPLC Retention.
2.6 Retention Mechanism.
2.7 General Column Mass Balance.
2.8 Partitioning Model.
2.9 Adsorption Model.
2.10 Total and Excess Adsorption.
2.11 Mass Balance in Adsorption Model.
2.12 Adsorption of the Eluent Components.
2.13 Void Volume Considerations.
2.14 Thermodynamic Relationships.
2.15 Adsorption-Partitioning Retention Mechanism.
2.16 Secondary Equilibria.
2.17 Gradient Elution Principles.
2.18 Types of Analyte Interactions with the Stationary Phase.
3 Stationary Phases (Yuri Kazakevich and Rosario LoBrutto).
3.2 Type of Packing Material (Porous, Nonporous, Monolithic).
3.3 Base Material (Silica, Zirconia, Alumina, Polymers).
3.5 Adsorbent Surface Chemistry.
3.6 Surface of Chemically Modified Material.
3.7 Polymer-Based Adsorbents.
3.8 Stationary Phases for Chiral Separations.
4 Reversed-Phase HPLC (Rosario LoBrutto and Yuri Kazakevich).
4.2 Retention in Reversed-Phase HPLC.
4.3 Stationary Phases for RPLC.
4.4 Mobile Phases for RPLC.
4.5 pH Effect on HPLC Separations.
4.6 Effect of Organic Eluent Composition on Analyte Ionization.
4.7 Synergistic Effect of pH, Organic Eluent, and Temperature on Ionizable Analyte Retention and Selectivity.
4.8 Examples of Applying pH Shift and Analyte pKa Shift Rules.
4.9 Effect of Temperature on Analyte Ionization.
4.10 Ion-Interaction Chromatography.
4.11 Concluding Remarks.
5 Normal-Phase HPLC (Yong Liu and Anant Vailaya).
5.2 Theory of Retention in Normal-Phase Chromatography.
5.3 Effect of Mobile Phase on Retention.
6 Size-Exclusion Chromatography (Yuri Kazakevich and Rosario LoBrutto).
6.1 Separation of the Analyte Molecules by Their Size.
6.2 Molecular Size and Molecular Weight.
6.3 Separation Mechanism.
6.6 Molecular Weight Distribution.
6.7 Effect of Eluent.
6.8 Effect of Temperature.
6.10 Solving Mass Balance Issues.
6.11 Aqueous SEC Applications.
7 LC/MS: Theory, Instrumentation, and Applications to Small Molecules (Guodong Chen, Li-Kang Zhang, and Birendra N. Pramanik).
7.2 Ionization Methods and LC/MS Interfaces.
7.3 Mass Analyzers.
7.4 Role of Instrumental Parameters on Ionization Efficiency in LC/MS.
7.5 Effect of Mobile-Phase Composition on Ionization Efficiency in LC/MS.
7.6 MS Interpretation.
7.7 Practical Applications.
8 Method Development (Rosario LoBrutto).
8.2 Types of Methods.
8.3 Defining the Method.
8.4 Method Development Considerations.
8.5 Method Development Approaches.
8.6 Effect of pH on UV Absorbance.
8.7 Analyte pKa—From an Analytical Chemist’s Perspective.
8.8 Reversed-Phase Versus Normal-Phase Separations.
8.9 Instrument/System Considerations.
8.10 Column Testing (Stability and Selectivity).
8.11 Concluding Remarks.
9 Method Validation (Rosario LoBrutto and Tarun Patel).
9.2 Validation Report.
9.4 Assignment of Validation Parameters.
9.5 Distinguishing Drug-Related and Non-Drug-Related Degradation Products.
9.6 Concluding Remarks.
10 Computer-Assisted HPLC and Knowledge Management (Yuri Kazakevich, Michael McBrien, and Rosario LoBrutto).
10.2 Prediction of Retention and Simulation of Profiles.
10.3 Optimization of HPLC Methods.
10.4 Structure-Based Tools.
PART II HPLC IN THE PHARMACEUTICAL INDUSTRY.
11 The Expanding Role of HPLC in Drug Discovery (Daniel B. Kassel).
11.2 Applications of HPLC/MS for Protein Identification and Characterization.
11.3 Applications of HPLC/MS/MS in Support of Protein Chemistry.
11.4 Applications of HPLC/MS/MS in Support of Assay Development and Screening.
11.5 Sources of Compounds for Biological Screening.
11.6 HPLC/MS Analysis to Support Compound Characterization.
11.8 Higher-Throughput Purification Strategies.
11.9 ADME Applications.
11.10 Fast Serial ADME Analyses Incorporating LC-MS and LC-MS/MS.
11.11 Parallel Approaches to Speeding ADME Analyses.
11.12 Automated “Intelligent” Metabolic Stability and Metabolite ID.
12 Role of HPLC in Preformulation (Irina Kazakevich).
12.2 Initial Physicochemical Characterization (Discovery Support).
12.3 Chemical Stability.
12.4 Salt Selection.
12.6 Preformulation Late Stage (Development Support).
13 The Role of Liquid Chromatography–Mass Spectrometry in Pharmacokinetics and Drug Metabolism (Ray Bakhtiar, Tapan K. Majumdar, and Francis L. S. Tse).
13.3 Tandem-Mass Spectrometry (MS/MS).
13.4 Sample Preparation Using an Off-Line Approach.
13.5 Automated Sample Transfer.
13.6 Sample Processing Using an On-Line Approach.
13.7 Matrix Effect and Ion Suppression.
13.8 Regulatory Requirements for LC/MS Method Validation.
13.9 Ritalin®: An Application of Enantioselective LC-MS/MS.
13.10 GleevecTM (STI571).
14 Role of HPLC in Process Development (Richard Thompson and Rosario LoBrutto).
14.1 Responsibilities of the Analytical Chemist During Process Development.
14.2 HPLC Separation Modes.
14.3 Sample Preparation.
14.4 HPLC Detectors.
14.5 Method Development.
14.6 In-Process Monitoring.
14.7 Impurity Identification.
14.8 Establishment of HPLC Selectivity by Stress Studies.
14.9 HPLC Method Validation.
14.10 Technology Transfer.
14.11 Concluding Remarks.
15 Role of HPLC During Formulation Development (Tarun S. Patel and Rosario LoBrutto).
15.2 Prerequisite for Analytical Chemists During Formulation Development.
15.3 Properties of Drug Substance.
15.4 Properties of Excipients.
15.5 Impact of Excipients on Degradation of API(s).
15.6 Test Methods for Most Common Dosage Forms in which HPLC Is the Primary Technique.
15.7 Forced Decomposition.
15.8 Compatibility of Excipients with API(s) (Type and Ratio).
15.9 Mass Balance.
15.10 Summary of Assay and Related Substances.
15.11 Uniformity of Dosage Units.
15.12 Blend Uniformity (BU).
15.13 Cleaning Verification.
15.16 Method Development.
15.17 Method Validation.
15.18 Testing of Samples.
15.19 Automation Opportunities.
15.20 Implementation of Alternative Technologies.
15.21 Challenges and Future Trends.
A15.1 Addendum (Common Functional Groups).
A15.1.2 Nitrogen Functional Groups.
A15.1.3 Ethers, Thioethers.
A15.1.4 Alkyl/Aryl Halides.
A15.1.10 Ring Transformations.
16 The Role of HPLC in Technical Transfer and Manufacturing (Joseph Etse).
16.2 Prerequisites for Transfer of HPLC Methods.
16.3 Types of Technical Transfer.
16.4 Different Approaches for Technical Transfer and Manufacturing.
16.5 Potential Pitfalls During Technical Transfer and Manufacturing.
PART III HYPHENATED TECHNIQUES AND SPECIALIZED HPLC SEPARATIONS.
17 Development of Fast HPLC Methods (Anton D. Jerkovich and Richard V. Vivilecchia).
17.2 Basic Theory.
17.3 Monolithic Columns.
17.4 Ultra-High-Pressure Liquid Chromatography.
17.5 Separations on Chips.
17.6 Optimizing Gradient Separations for Speed.
17.7 Instrumental Requirements for Operating High-Efficiency Columns.
18 Temperature as a Variable in Pharmaceutical Applications (Roger M. Smith).
18.1 The Influence of Temperature on Chromatography.
18.2 Effects on Method Transferability and Reproducibility.
18.3 Elevated Temperature and Pharmaceutical Separations.
18.4 Superheated Water Chromatography.
18.6 Subambient Separations.
19 LC/MS Analysis of Proteins and Peptides in Drug Discovery (Guodong Chen, Yan-Hui Liu, and Birendra N. Pramanik).
19.2 General Strategies for Analysis of Proteins/Peptides.
19.3 Applications for Biotechnology Products and Drug Targets.
20 LC-NMR Overview and Pharmaceutical Applications (Maria Victoria Silva Elipe).
20.2 Historical Background of NMR.
20.4 LC-MS-NMR (or LC-NMR-MS or LC-NMR/MS).
21 Trends in Preparative HPLC (Ernst Kuesters).
21.2 Method Development in Preparative HPLC.
21.3 Columns and Stationary Phases.
21.4 Choice of Preparative LC Technology.
21.5 Detection Tools.
22 Chiral Separations (Nelu Grinberg, Thomas Burakowski, and Apryll M. Stalcup).
22.2 Separation of Enantiomers Through the Formation of Diastereomers.
22.3 Molecular Interactions.
22.3.5 Charge Transfer.
22.4 Mixed Types of Interaction.
22.5 Ligand Exchange.
22.6 Chiral Mobile Phases.
22.7 Method Development for Chiral Separation.
22.8 Concluding Remarks.
CHEMICAL AND DRUG COMPOUND INDEX.